MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-11-2025
Evolent Health Revenue 2011-2026 | EVH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Evolent Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 382 M | 248 M | 925 M | 846 M | 627 M | 435 M | 254 M | 96.9 M | - | 25.7 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 925 M | 25.7 M | 427 M |
Quarterly Revenue Evolent Health
| 2025-Q2 | 2024-Q2 | 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 444 M | 647 M | 511 M | - | 353 M | - | 297 M | 248 M | 222 M | 222 M | 215 M | 247 M | 240 M | 217 M | 221 M | 237 M | 220 M | 192 M | 198 M | 193 M | 150 M | 144 M | 140 M | 114 M | 108 M | 107 M | 106 M | - | -448 K | -14 K | - | - | - | -16.8 M | -11.3 M | - | -3.17 M | -5.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 647 M | -16.8 M | 192 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 5.73 | 1.78 % | $ 92 M | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 35.04 | 0.29 % | $ 1.61 B | USA |
 |
Phreesia
PHR
|
356 M | $ 11.67 | 3.46 % | $ 637 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 5.58 | 0.18 % | $ 983 M | USA |
 |
10x Genomics
TXG
|
619 M | $ 21.08 | 0.81 % | $ 2.47 B | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 7.23 | 0.7 % | $ 124 M | USA |
 |
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.08 | 0.92 % | $ 802 M | USA |
 |
Schrödinger
SDGR
|
256 M | $ 11.69 | 2.5 % | $ 859 M | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.13 | 2.02 % | $ 190 K | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
HealthStream
HSTM
|
292 M | $ 21.46 | 1.08 % | $ 652 M | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 1.8 | - | $ 9.37 M |  China |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.1 | - | $ 76.9 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 83.84 | 1.66 % | $ 7.22 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Progyny
PGNY
|
298 M | $ 18.14 | 2.17 % | $ 1.56 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 3.09 | -3.13 % | $ 245 M | China |
 |
Veeva Systems
VEEV
|
3.2 B | $ 182.53 | 2.5 % | $ 29.9 B | USA |